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Tamoxifen (TMX) is one of the most widely used form of endocrine therapy for patients with breast cancer (Furr & Jordan, 1984) . Several trials have established the importance of this agent in delaying relapse (Baum et al., 1985) and in significantly prolonging survival (Fischer et al., 1987) . It is generally recognised that breast cancer patients with positive oestradiol (E2) and progesterone (P) receptors (R) respond better to TMX than those with negative receptors. But there are both clinical (Baum et al., 1985; Vogel et al., 1987) and experimental (Miller et al., 1984; Katzenellenbogen et al., 1985) data which suggest that the effects of TMX on tumour growth should not be considered as merely an inhibition of the action of oestrogens. Several reports have pointed out the quantitative (Adam et al., 1980; Kemp et al., 1983) and qualitative (Wakeling & Slater, 1980; Jordan, 1984) importance of TMX metabolism for the expression of drug activity in vitro.
Up to now four metabolites have been identified in patients: N-desmethyltamoxifen (NDT), 4-hydroxytamoxifen (4-OHT) and the more recently described metabolites Y (Jordan et al., 1983) and Z (Kemp et al., 1983) . In a recent study (Milano et al., 1987) we described on a limited number of patients an updated metabolic profile of TMX in plasma. Marked differences were observed between the beginning of treatment and the time steady state was reached (one month or more of continuous TMX administration). Considering that the mechanism of action of TMX is still poorly understood (Rochefort, 1987) it seemed appropriate to reevaluate the importance of TMX metabolism in the expression of drug activity in vitro. To our knowledge, no such unified study including TMX, NDT, Y and Z has been reported until now. However, significant contributions concerning in vitro effects of TMX, NDT, 4-OHT (Reddel et al., 1983) and Y (Jordan et al., 1983) (Milano et al., 1987 (Hayward et al., 1978) .
The comparison of respective blood concentrations of TMX and metabolites according to the treatment response was done using the Mann-Whitney non-parametric test.
In vitro study
Relative binding affinities (RBAs) To determine the ability of TMX and metabolites to compete for E2R, a constant concentration of 3H-E2 (5 nM) was incubated for 16 h at 0°C on a pool of E2R positive cytosols from human breast cancers (mean value=42fmolmg protein-1; Milano et al., 1983 ). There were increasing concentrations of ligands (unlabelled E2, TMX and metabolites, 10-10 to 10-I M). Rochefort (Montpellier, France) and CAL 18B (Gioanni et al., 1985) a cell line obtained in our institute. CAL 18 B was considered as negative in both E2R (2 fmol mg protein-1) and PR (llfmolmg protein-1).
Cell lines were maintained in DMEM medium (Gibco, Paisley, UK) supplemented with 5% fetal bovine serum (Seromed, Biochrom KG, Berlin), 600 pg 1-insulin, 5mgl-1 transferrin, 5mM glutamine, 160mgl-1 gentamycin, 50,OOOLUI1 penicillin, 50,OOOpg -1 streptomycin. The final E2 concentration in the medium was below 10-"M. Cells were incubated at 37-C in a humidified atmosphere of 5% CO2 in air. Cells were suspended in 24-well plates (Falcon 3047, Beckton Dickinson, Lincoln Park, NJ, USA). Distributions were made in quadruplicate or sextuplicate depending on the protocol conditions. Initial conditions were 7,000-12,000 cells per well in 400p of medium. After cell adhesion (24-48h) the medium was removed and a medium supplemented with drug(s) was added. TMX and metabolites were tested between 2 x 10-8 and 10-SM. Activity of TMX and metabolites was also evaluated at 5 x 10 -M in presence (8 days co-incubation) of E2 5 x 10-9, 5 x 10-8 and S x 10-7 M. Medium was renewed daily until the end of experimentation (6-9 days). Dilutions of TMX and metabolites were made from the stock solution in ethanol by successive dilutions in the medium, so that the final alcohol concentration in the medium did not exceed 0.2%; we tested that alcohol had no effect on cell proliferation at this concentration. At the end of the fixed incubation period, wells were washed with Medium 199 with Hepes (Gibco, Paisley, UK). Cells were then incubated with the same medium supplemented with 5% fetal bovine serum and tritiated thymidine (1.4pCiml-1) for 16h. Cells were then washed three times with cold PBS Medium (Gibco, Paisley, UK) and precipitated with cold TCA 10% (w/v) for 30min. After removal of TCA, denaturated cells were solubilised with I N NaOH and the solution was neutralised with 6NHCI. Radioactivity was measured on a Packard Tricarb 460. Cytostatic effects were quantified as percentage of radioactivity per well as compared with controls without drugs. Cytotoxic effect was evaluated by morphometry and by loss of adhesion to the support. IC50 was defined as the drug concentration causing 50% inhibition of cell growth, with reference to untreated control cells.
Metabolic activity of cell lines Media containing 2 x 10-6 M of compound (TMX and/or metabolites) were incubated in presence of MCF-7 and CAL-18 B cells (200,000 cells per 25cm2 flask) for 2-3 days. Controls without cells were run in parallel. After the incubation period, media were collected and analysed by HPLC to evaluate the drug profiles. Five hundred p1 of medium was extracted by 2 x 2 ml diethyl ether and HPLC was performed as described above. The percentage of remaining concentration was expressed as follows: (C cells/C control) x 100, where C cells= concentration of drug(s) in presence of cells and C control = concentration of initial drug in control medium at the same time and without cells.
Resuls
Pharmacokinetic study Pharmacokinetic profles in treated patients Figure 2 shows the time-concentration profile of TMX and metabolites after the first oral dose (30mg) for 12 patients with breast cancer. 4-OHT excepted, all metabolites were present in blood from the first hour and respective plasmatic peaks occurred between 4 and 6h. Seventy-eight patients were explored for blood TMX and metabolites once steady state was considered as reached (one month or more). Table I gives the mean concentrations and the respective proportions of TMX and related species at the first dose (in terms of percentages of total and at the steady state (in terms of percentages of total plasmatic concentration). It appears that a large inter-patient variability exists for the individual capacity to produce metabolites and particularly 4-OHT, which had the highest coefficient of variation. Clinicalpharmacokinetic correlations Figure 3 represents, for the 13 evaluable patients receiving TMX alone, the distribution of serum levels of TMX and metabolites according to treatment response. There were no significant differences between progressive disease, PD (nine patients) Figure 5 shows the dose-response curves of each product on CAL 18B cells (E2R and PR negative). A marked growth-inhibiting effect of TMX and metabolites was evident at a concentration range superior to that observed for MCF 7 cells. Here, TMX was the most active, 4-OHT and NDT the least; at IC5O, the order of activity for all products was TMX>Y>Z>4-OHT=NDT. However, the differences in ICSO between TMX and metabolites were hardly evaluable. All drugs, except metabolite Y, were cytotoxic at 10-M. Activity of metabolites in mixture According to the pharmacokinetic results, the respective proportions of TMX and metabolites tested, corresponded to those shown in Table I : Dl, TMX=64.5, NDT=28, Y=4.5, Z=2.5, 4-OHT=0.5; Css, TMX=27.5, NDT=61, Y=4, Z=7, 4-OHT=0.5. Figure 6 shows the dose-response curves obtained on MCF-7 and CAL-18 B cells for both TMX and drug mixtures in proportions corresponding to D1, as compared to those of Css. On MCF-7 cells, for all concentrations tested, Dl and Css showed a similar efficacy which was also globally comparable to TMX alone. Against CAL-18 B, Dl and Css mixtures were also equipotent and more efficient than TMX alone. Here again for a comparable effect, MCF-7 required a lower concentration range than CAL-18 B.
Effect of E2 On CAL-18 B cells, E2 had no influence against the growth inhibiting effects of TMX and metabolites. In contrast (Figure 7) , a concentrationdependent reversal effect of E2 was noted on MCF-7 cells; with E2 and drugs being equimolar (5x 10-7M) the effects of metabolites Y and Z were completely reversed, TMX and NDT partially reversed, and 4-OHT the least affected. 
Disassi
The aim of this study was to evaluate the quantitative and qualitative importance of TMX metabolism by both in vivo and in vitro investigations. All metabolites reported so far (Furr & Jordan, 1984) were included in this study. Lien et al. (1988) recently described 4-hydroxy-N-desmethyltamoxifen as a new TMX metabolite present in human bile; it was not considered in our analysis but it is quite possible that its physico-chemical nature corresponds to the unidentified polar metabolite observed in our study. Mechanism of action of TMX is far from simple. Apart from the direct effect of TMX via E2R, there are numerous interactions with cellular targets: binding to the so-called but still unidentified antioestrogenic binding sites different from E2R (Miller et al., 1984) , induction of TGF-f (Knabbe et al., 1987) , inhibition of calmodulin (Gulino et al., 1986) and phospholipid/calcium dependent protein kinase (Su et al., 1985) . These data must be recalled when discussing TMX activity.
A complete metabolic study of TMX was undertaken on a large set of patients with special attention paid to the elaboration of precise drug profiles at Dl and Css. All metabolites considered could be detected at the first drug intake. Confirming initial data (Wakeling & Slater, 1980) (Milano et al., 1987) , NDT was the major compound present in blood at the steady state; 4-OHT was quantitatively the minor metabolite but with a large inter-patient variability.
The heretofore less explored metabolites Y and Z may be considered as being significantly present in blood. We considered the steady state reached after at least 4 weeks of continuous treatment, which is justified for TMX, but NDT steady state is obtained later, after 8 weeks (Furr & Jordan, 1984) . From Dl to Css, the parallel increase in proportion of demethylated metabolites (NDT and Z) leads to the conclusion that demethylation may be a major route of TMX metabolism in human. These pharmacokinetic observations constituted the clinically relevant basis for comparing TMX and metabolite activity in vitro.
Dose-response curves obtained on breast cancer cell lines with E2R (MCF-7) and without E2R (CAL-18 B) call up several comments. It was striking to note that the order of potency of the five products tested against MCF-7 cells was comparable to that of their RBAs for E2R. This confirms and extends the work of Reddel et al. (1983) where, against MCF-7, 4-OHT was 100-167-fold more potent than both TMX and NDT in producing dose-dependent decreases in cell proliferation rate. This was also correlated with their RBAs for E2R. These data taken together are in line with a specific anti-oestrogenic effect of TMX and metabolites via the E2R system. But results obtained on the E2R negative cell line CAL-18 B modulate this conclusion and indicate that TMX and metabolites, at a higher concentration range, may be active in the absence of E2R. In this case, their order of efficacy did not parallel their RBAs for E2R, and in contrast with the results for MCF-7, 4-OHT was the least active. In addition, E2 co-incubated with TMX and/or metabolites reversed the drugs' effects only for E2R positive cels.
In a comparable study, but limited to TMX, Reddel et al. (1985) observed that E2R positive cells were more sensitive (4-75-fold) than E2R negative ones to growth-inhibiting effects of TMX. Taken together with the conclusions of Briand & Lykkesfeldt (1984) and those of Taylor et al. (1984) , the present data are compatible with a unified concept postulating differential effects of TMX and metabolites according to a concentration threshold. In the present work and according to the type of drug considered, this threshold was located between 2xlO-6 and 10-5M. Below this level, TMX and metabolites would act primarily through the E2R system by exerting a cytostatic effect; above this level, a less specific, E2R independent, cytotoxic effect would be implicated. The pharmacokinetic data reported here indicate that, at the steady state, total plasmatic concentrations of TMX plus metabolites are highly variable in this range of 2 x 10-6M (Table I) . Thus, during standard TMX treatment (30mg daily) or alternative dosage (20 or 40mg daily) it is conceivable that both E2R specific and E2R independent mechanisms may be implicated in the overall expression of drug activity. We thus feel it could be of interest to know, in a larger patient sample than in our study, whether response (or stable disease) in E2R negative patients could be related to high drug levels in plasma. It is thus not surprising that recent studies on TMX concluded that the benefit of TMX is independent of E2R status (Baum & Nato, 1985) and that others considered that response to endocrine therapy is only a facet of the generally favourable prognosis of E2R positive patients rather than the sole explanation (Shek et al., 1987 (Wilkinson et al., 1982) , so that efficient plasmatic levels would be reached quicker. On the other hand, the existence of this dose-response relationship in both E2R positive and negative cells may shed some light on the controversial literature data concerming the efficiency of high dose TMX (Manni & Arafah, 1981; Stewart et al., 1982) . Recently, Watkins (1988) 
